Up­dat­ed: FDA to im­port more of com­mon can­cer drug from Chi­na af­ter In­di­an site clo­sure

The US is plan­ning to im­port more dos­es of the chemother­a­py cis­platin from Chi­na, which is still in short sup­ply af­ter an In­di­an site vol­un­tar­i­ly shut down af­ter qual­i­ty prob­lems were high­light­ed by FDA in­spec­tors late last year.

A spokesper­son for Apo­tex, a gener­ic med­i­cine com­pa­ny that is dis­trib­ut­ing the Chi­nese-made drug in the US, said that the com­pa­ny is ex­pect­ing 10 more batch­es of a ver­sion of cis­platin man­u­fac­tured by Qilu Phar­ma­ceu­ti­cal, which will ar­rive for dis­tri­b­u­tion from Chi­na lat­er this week.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.